About Dr. Gordon
Dr. Jessica Gordon is an Associate Attending Physician in the Division of Rheumatology at Hospital for Special Surgery and an Associate Professor of Clinical Medicine at Weill Cornell Medicine. She specializes in the treatment of patients with systemic sclerosis (scleroderma), and her research focus is developing improved therapies for patients with this condition. She also specializes in the care patients with Raynaud phenomenon, mixed connective tissue disease, interstitial lung disease associated with connective tissue disease, Sjogren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis, and other conditions. She is the HSS Scleroderma clinic chief. She has been recognized for several years as a "Top Doctor" by Castle/Connolly and New York magazine.
Dr. Gordon completed her undergraduate studies at Brown University in 1993. She received her MD degree from State University of New York at Stony Brook where she graduated Alpha Omega Alpha. She completed her internal medicine residency and chief residency at Georgetown University Hospital in Washington, DC. She then went on to complete her fellowship in Rheumatology at Hospital for Special Surgery. Following this she joined the faculty at HSS in 2010 where she continues to practice Rheumatology.
Dr. Gordon conducts clinical and translational research in systemic sclerosis. She is an investigator in multiple clinical trials and observational studies with this focus. She has been the recipient of numerous grants and awards including the Kellen Family Clinical Scientist Development Award, the Scleroderma Foundation New Investigator Grant, the Charles L. Christian Award for Excellence in Musculoskeletal Research, and the American College of Rheumatology Distinguished Fellow Award.
Departments
Specialized Centers
Scleroderma, Vasculitis & Myositis Center of Excellence
Special Expertise
Associated interstitial lung disease
Connective tissue disease
Eosinophilic fasciitis
Inflammatory arthritis
Inflammatory myopathy
Localized scleroderma/Morphea
Mixed connective tissue disease
Raynaud phenomenon
Rheumatoid arthritis
Sjogren’s syndrome
Systemic lupus erythematosus
Systemic sclerosis/scleroderma
Procedures
Intra-articular and intra-bursal aspirations and injections
Patient Stories
Insurance
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Credentials
Appointments
Associate Attending Physician, Hospital for Special Surgery
Associate Professor of Medicine, Weill Cornell Medical College
Affiliations
Member, American College of Rheumatology
Member, American Medical Association
Scleroderma Foundation Medical Advisory Board
Certification
Rheumatology, 2008
Internal Medicine, 2005
Awards
Castle Connolly Top Doctors in New York Metro Area, 2017-2022
Castle Connolly Regional Top Doctor, 2017-2021
New York Magazine Top Doctors, 2017-2022
Exceptional Women In Medicine: 2019, 2020
Charles L. Christian Award for Excellence in Musculoskeletal Research, 2010
Department of Medicine Fellow Award - Finalist, 2010
American College of Rheumatology Distinguished Fellow Award, 2009
Certificate of Appreciation – Scleroderma Foundation – Tristate Chapter, 2009
Donald Knowlan Award, Georgetown University Hospital, Dept. of Internal Medicine, 2005
Janet Glasgow Memorial Achievement Citation, American Medical Women’s Society, 2002
Alpha Omega Alpha Honor Society, 2001
Education
MD, State University of New York at Stony Brook, Stony Brook, NY 2002
MS, Clinical Investigation, Cornell University, NY 2010
Internship
Internal Medicine, Georgetown University Hospital, Washington, DC
Residency
Internal Medicine, Georgetown University Hospital, Washington, DC
Fellowship
Rheumatology, Hospital for Special Surgery
State Licensure
Languages
English, Spoken by Office Staff: Spanish
Publications by Dr. Gordon
For all publications, please see the PubMed listing.
Patient Education
- Scleroderma and Systemic Sclerosis (SSc): An Overview
- Kellen Award Program Fosters Emerging Physician-Scientists
Professional Education
- Sjögren’s Syndrome-associated Interstitial Lung Disease Treated with Immunosuppression
- Progressive Dyspnea and Cough in a Healthy, Young Man
Blog Posts
Selected Books/Chapters
- Gordon JK, Goldenberg D, Erkan D, Lockshin M. (2009) Difficult Situations in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, Volume 10. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. (Eds. Ricard Cervera, Joan Carles Reverter and Munther Khamashta), 215 – 233.
Selected Presentations
- Gordon JK, Spiera RF, Mersten JN, Wildman HF, Taime Z, Hackett, NR, Vukelic S, Kirou K, Crow MK. Does Treatment with Imatinib Modify Gene Expression in the Skin and Peripheral Blood Mononuclear Cells of Patient with Systemic Sclerosis? American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
- Gordon JK, Gomberg-Maitland M, Segal B, Domsic R, Shah A, Hummers L, Steen V, Horn E and the PHAROS Investigators. Difficulty Using World Health Organization Criteria to Categorize Pulmonary Hypertension in Patients with Systemic Sclerosis. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
- Spiera RF, Gordon JK, Mersten J, Magro CM, Mehta M, Wildman HF, Kloiber SA, Kirou KA, Lyman, S, Crow MK. Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
- Gordon JK, Vukelic S, Magro CM, Mersten J, Wildman HF, Crow MK, Kirou KA and Spiera RF. Histologic and Molecular Basis of Improved Skin Scores in Scleroderma Patients Treated with Imatinib Mesylate (Gleevec.) Abstract 1727. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
- Gordon JK, Mersten J, Lyman S, Kloiber SA, Wildman HF, Crow MK, Kirou KA and Spiera RF. Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial. Presentation 606. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
- Taimeh Z, Gordon JK, MacDermott EJ, Barillas L, Mersten J, Duculan R, Spiera RF, Crow MK, Kirou KA. Elevated sVEGFR-1 Is a Candidate Biomarker for Pulmonary Dysfunction in Patients with Systemic Sclerosis. Abstract 466. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
- Spiera RF Gordon JK Mehta M Kirou KA Lyman S Kloiber SA Crow MK. (2008). Phase IIa Trial of Imatinib Mesylate (Gleevec) in the Treatment of Diffuse Systemic Sclerosis - An Interim Analysis. Arthritis and Rheumatism 58(10): S1222.
- Gordon JK, Magid S, Berman E. (2008). Elevations in Creatine Kinase Occur Frequently in Patients Treated with Imatinib Mesylate (Gleevec.) Abstract F15/469, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
- Gordon JK, Taimeh Z, Markopoulou A, Mersten J, Crow MK, Kirou KA. (2008). High Levels of Activated ERK in Monocytes of Patients with Scleroderma. Abstract F2/456, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
- Gordon JK, Steen V. (2005). African American Scleroderma Patients Have Altered Body Image. Arthritis and Rheumatism 52(9): S585.
Research
Research Interests
Scleroderma
Clinical Trials
- Abatacept (CTLA4-lg) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener’s) (ABROGATE)
- Gleevec in the Treatment of Systemic Sclerosis - EXTENSION STUDY
- Scleroderma Registry and Repository (Old IRB #26069)
- Randomized, Double-Blind, Placebo-Controlled Trial of IL1-Trap, Rilonacept in Systemic Sclerosis-A Phase I/II Biomarker Trial (Old IRB #14115)
- The Myositis Registry and Repository - 2016
- VCRC Genetic Repository One Time DNA Protocol - 2016
- The Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension: a Multicenter Study Performed by from the Scleroderma Clinical Trials Consortium (PHAROS)
- Prospective Registry of Early Systemic Sclerosis (PRESS)- Phenotypic, Serologic, and Biomarker/Genetic Characteristics of Early Diffuse Cutaneous Scleroderma
- A Double Blind, Randomized, Placebo-Controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients with “Systemic Sclerosis associated Interstitial Lung Disease” (SSc-ILD)
- Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener’s Granulomatosis and Microscopic Polyangiitis
- An International, Open Label, Randomized Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis
- The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
- A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects with Giant Cell Arteritis
- Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension
- ASCI: A Randomized, Double-blind, Placebo-controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
- Nilotinib in the Treatment of Systemic Sclerosis
- Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Prospective, Observational Safety Study Of Patients With Granulomatosis With Polyangiitis (Wegener’s) Or Microscopic Polyangiitis Treated With Rituximab
- Phase II/III, Multicenter, Randomized, Double-blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab vs. Placebo in Patients with Systemic Sclerosis
- Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients with Ischemic Digital Ulcers Associated with Systemic Sclerosis
- Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica
- The Myositis Registry and Repository - 2011
- Abatacept in Large Vessel Vasculitis
- VCRC Genetic Repository One Time DNA Protocol - 2013
Patient Registries
- Dr. Gordon is a principal investigator for these patient registries.
Industry Relationships
Industry Relationships
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Gordon as of March 01, 2023.
- Cumberland Pharmaceuticals - Research Support
- EICOS Sciences - Research Support
- Genentech - Research Support
- Regents of UCLA - Research Support
- Scleroderma Research Foundation - Advisory Board; Research Support
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.